Endometriosis Patients Undergoing Quinagolide Treatment

Instituto Valenciano de Infertilidad, IVI VALENCIA5 enrolled

Overview

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Hyperprolactinemia Endometriosis

Interventions

ENDOMETRIAL BIOPSYPROCEDURE

Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 37 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hyperprolactinemia * Unexplained infertility * Endometriosis

Locations (1)

Instituto Valenciano de Infertilidad

Valencia, Valencia, Spain

Outcomes

Primary Outcomes

observation of three month treatment with Quinagolida in endometriosis patients

Time frame: onset and three months after onset

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.